Aspergillus lentulus: An Under-recognized Cause of Antifungal Drug-Resistant Aspergillosis

Samant Nematollahi,1* Nitpong Permpalung,1*, Sean X. Zhang,2, Megan Morales,2, and Kieren A. Marr1*

1Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, 2Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, 3Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, and 4Division of Infectious Diseases, Department of Medicine, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA

Aspergillus lentulus is a drug-resistant species that is phentypically similar to A. fumigatus. It was discovered as a cause of azole-breakthrough disease, consistent with in vitro resistance. Clinical labs can misidentify the species as fumigatus based on phenotypic typing. We describe 4 recent cases and provide a brief review.

Keywords. Aspergillus lentulus; cryptic species; DNA sequencing; MALDI-TOF MS; multidrug resistance; pulmonary aspergillosis.

Aspergillus fumigatus, once considered 1 species, actually encompasses many members in a complex of phenotypically similar but molecularly distinct “cryptic” species [1]. Molecular typing has led to recognition of A. lentulus and A. thermomutatus, among others [2]. Cryptic species cause 3%–15% of invasive aspergillosis (IA) cases but are under-recognized by labs that use phenotypic identification alone [3–6]. Correct identification is important, as some of these species can be resistant to triazoles and amphotericin B.

Aspergillus lentulus was discovered as a cause of IA in hematopoietic stem cell transplant (HSCT) recipients in Seattle, Washington [4, 7]. Although phenotypically identified as A. fumigatus, it was found to be genetically distinct and highly drug resistant. It has been suggested that A. lentulus infection causes higher mortality compared with A. fumigatus (>60%) [3]. We highlight 4 recent cases at 2 US centers, identified after identification methods were enhanced to include matrix-assisted laser desorption ionization–time-of-flight mass spectrometry (MALDI-TOF MS) and antifungal drug susceptibility testing (minimum inhibitory concentration was determined by the broth microdilution method recommended by CLSI M38-A3).

PATIENT CASES

The first patient was a 47-year-old man with alcoholic cirrhosis and a liver transplant who had dyspnea and a mass-like consolidation in the right upper lobe on computed tomography (CT). Serum beta-D-glucan (BDG; Fungitell, Associates of Cape Cod, Inc.) and galactomannan (GM; Platelia, BIO-RAD) were positive (500 pg/mL and 0.82 index, respectively). Tracheal aspirate cultures grew Aspergillus lentulus, with susceptibilities noted in Table 1. The patient was treated with voriconazole and micafungin for 2 weeks, then voriconazole monotherapy. Repeat CT chest and serum GM showed improvement after 3 months of therapy. Due to dizziness and vivid dreams, voriconazole was switched to isavuconazole, and he continued to show clinical improvement.

The second case was a 76-year-old man with untreated pulmonary sarcoidosis who presented with months of weight loss and cough. CT showed bilateral upper lobe interstitial fibrosis, bronchiectasis, and reticulonodular opacities. His bronchoalveolar lavage (BAL) cultures grew both Aspergillus fumigatus and Aspergillus lentulus, with susceptibilities in Table 1. He was treated with voriconazole, with no change in CT findings 4 months later. Voriconazole was discontinued with elevations in liver chemistry tests and biopsy suggestive of drug-induced liver injury. He remained clinically stable despite persistent CT findings.

The third patient was a 54-year-old man with pulmonary sarcoidosis requiring prednisone therapy and metastatic pancreatic cancer treated with fluorouracil who presented with fevers and hypoxia. BAL grew A. nidulans, A. lentulus, A. calidoustus, and Mycobacterium avium intracellulare. Susceptibilities for A. lentulus are noted in Table 1. Antifungal therapy was initially reserved with negative serum biomarkers (BDG <31 and GM 0.15). After 2 months of observation, he was admitted with fevers and chest CT showing multiple noncalcified pulmonary nodules. With the increase in size of the pancreatic mass and new liver lesions, concern for metastatic cancer was raised. Despite treatment with isavuconazole, micafungin, and antibacterials, his clinical condition deteriorated, and he was transitioned to comfort measures.

The fourth case was a 67-year-old man with transthyretin amyloidosis with cardiac involvement who underwent heart transplantation 1 month before presenting with dry cough. CT showed a new right middle lobe mass, multifocal nodules, and ground glass opacities. BAL grew A. fumigatus. Serum BDG
was >500 pg/mL, and serum GM index was 0.42. He was initially treated with voriconazole and micafungin. Voriconazole was changed to liposomal amphotericin after rapid progression in the mass size with cavitation. Sequencing of the isolate was performed by UT Health San Antonio, correcting identification to A. lentulus, with susceptibilities in Table 1. Voriconazole was changed to posaconazole, with complete resolution of symptoms but persistent loculated cavitations with surrounding ground glass and stable nodules on imaging after 14 months of therapy.

**Patient Consent**

Patients were described after written consent was obtained at Johns Hopkins University (JHU; Baltimore, MD, USA, #1–3) and Virginia Commonwealth University (Richmond, VA, USA, #4). This work did not require local ethical committee review.

### DESCRIPTION AND IDENTIFICATION

*Aspergillus lentulus* was first described in 2004 from BAL samples of 4 patients that represented 5% of HSCT patients in a retrospective study screening for itraconazole resistance [7]. These isolates were identified as a new, genetically distinct species, named *Aspergillus lentulus* [8]. *Lentulus* is derived from the Latin word “lentus,” which means tough and slow, chosen to reflect its sporulation characteristics. Macroscopically, colonies sporulate slowly and appear white, before generating pale green-blue conidia similar to *A. fumigatus* (Figure 1). Compared with *Aspergillus fumigatus sensu stricto*, *Aspergillus lentulus* has smaller, globose vesicles with shorter conidial heads, and it exhibits increased susceptibility to temperatures >37°C [3, 8]. The species is genetically distinct, enabling molecular identification that relies on DNA sequence (or polymorphism) in internal transcribed spacer (ITS) rDNA and beta-tubulin (benA) [3]. Additionally, MALDI-TOF MS can distinguish between *A. lentulus* and *A. fumigatus* [9].

In Baltimore, we identified reported cases in 2020, after the lab initiated routine MALDI-TOF MS (Bruker MALDI Biotyper) with antifungal susceptibility testing on *Aspergillus* isolates recovered from BAL. All 4 isolates in this case series were confirmed by DNA sequencing. Three additional cases of *A. lentulus* infections were identified during preparation and review of the manuscript. These isolates had not been appreciated as a cause of disease at JHU previously, suggesting misidentification using phenotypic methods. Environmental changes promoting epidemiologic shifts and increased case recognition cannot be ruled out. Infections in people from 2 centers minimize the likelihood of common exposures.

In these cases, the organism was associated with IA and/or recovered as a colonizer in the airway in the less immunosuppressed patient with sarcoidosis. This follows the pattern described for all *Aspergillus* species, which cause disease along the spectrum of airway colonization to tissue invasion, influenced

### Table 1. Patient Characteristics of *Aspergillus lentulus* Cases

| No | Age, Sex | Underlying Disease | Immunosuppression | Source | Susceptibility (MIC), ug/mL | Prior Antifungal | Imaging | Serum BDG (Normal <80 pg/mL) | Serum GM Index (Normal <0.5) | Outcome |
|----|----------|--------------------|-------------------|--------|-----------------------------|-----------------|--------|----------------------------|-----------------------------|---------|
| 4  | 67M      | TTR amyloidosis & heart transplant | Lung | Lung | Lung | Lung | None | None | Mass-like consolidation in RML | Interstitial fibrosis and bronchiectasis, scarring, reticulonodular opacities | Improved but with residual CT changes | Deceased | No follow-up | Improved | Outcome |
|   | 54M      | Pulmonary sarcoidosis & metastatic pancreatic cancer | Lung | Lung | Lung | Lung | None | None | Mass-like consolidation in RUL | >500 | Serum BDG (Normal <80 pg/mL) | BAL GM Index (Normal <0.5) | Improved | Outcome |
|   | 78M      | Pulmonary sarcoidosis | Lung | Lung | Lung | Lung | None | None | None | Interstitial fibrosis and bronchiectasis, scarring, reticulonodular opacities | 0.42 | Serum GM Index (Normal <0.5) | Improved | Outcome |
|   | 47M      | Liver transplant | Underlying Disease | Underlying Disease | Underlying Disease | Underlying Disease | Underlying Disease | Underlying Disease | Underlying Disease | Underlying Disease | Improved | Outcome |
|   | 43       | 4                  | Patient #          | 3       | 2     | 1     | 
|   | 3        | 67M                | Age, Sex           | 67M     | 54M   | 78M   | 47M    | Patient #   | Lung | Lung | Lung | Lung | Lung | Lung | None | None | Mass-like consolidation in RML | Interstitial fibrosis and bronchiectasis, scarring, reticulonodular opacities | Improved but with residual CT changes | Deceased | No follow-up | Improved | Outcome |
|   | 2        | None               | None               | None    | None  | 4     | Isavu: 2 | Posa: 0.25 | Pulmonary sarcoidosis | Lung | Lung | Lung | Lung | Lung | Lung | None | None | Mass-like consolidation in RUL | >500 | Serum BDG (Normal <80 pg/mL) | BAL GM Index (Normal <0.5) | Improved | Outcome |
|   | 1        | None               | None               | None    | None  | 4     | Isavu: 2 | Posa: 0.25 | Lung | Lung | Lung | Lung | Lung | Lung | None | None | Mass-like consolidation in RUL | >500 | Serum BDG (Normal <80 pg/mL) | BAL GM Index (Normal <0.5) | Improved | Outcome |
|   | 0.25     | None               | None               | None    | None  | 4     | Isavu: 2 | Posa: 0.25 | Pulmonary sarcoidosis | Lung | Lung | Lung | Lung | Lung | Lung | None | None | Mass-like consolidation in RUL | >500 | Serum BDG (Normal <80 pg/mL) | BAL GM Index (Normal <0.5) | Improved | Outcome |
|   | 0.25     | None               | None               | None    | None  | 4     | Isavu: 2 | Posa: 0.25 | Pulmonary sarcoidosis | Lung | Lung | Lung | Lung | Lung | Lung | None | None | Mass-like consolidation in RUL | >500 | Serum BDG (Normal <80 pg/mL) | BAL GM Index (Normal <0.5) | Improved | Outcome |

**Abbreviations:** AmB, amphotericin B; BAL, bronchoalveolar lavage; BDG, beta-D-glucan (Fungitell, Associates of Cape Cod, Inc.); GM, galactomannan (Platelia, BIO-RAD); Isavu, isavuconazole; Itra, itraconazole; MIC, minimum inhibitory concentration (determined by broth microdilution method recommended by CLSI M38-A3); Mica, micafungin; Posa, posaconazole; RML, right middle lobe; RUL, right upper lobe; Terb, terbinafine; TTR, transthyretin; Vori, voriconazole.
by patient risks. *Aspergillus lentulus* has been reported to cause disease in people with diverse risks, including transplant and onco-logy patients and people with chronic pulmonary disease, including that caused by cystic fibrosis [10,11].

To our knowledge, this is the first literature description of *A. lentulus* infections in the United States outside of Seattle, where it was first described. Cases have been reported in Spain, Italy, Belgium, Switzerland, Denmark, the Netherlands, Brazil, Argentina, Japan, China, Turkey, Australia, and Canada [5, 10, 11–18, 19–22]. Whether the species has a unique environ-mental niche is not clear. It has been recovered from soil and beach sand and has been identified as cause of disease in aquatic mammals and cats [23–26]. As it is tolerant to extreme growth conditions, including high pH and salt concentrations, it is likely to be widely dispersed and is being evaluated for bio-degradation of toxic compounds [27]. It was among a small number of organisms identified as persistently recovered over 3 flights to the international space station [28]. Environmental azole use may select growth; it was recovered, along with other species, from azole-treated vineyards in Portugal [29].

The majority of cases have been reported in transplant pa-tients and people with other immunocompromising states, including receipt of systemic corticosteroids [5, 10, 12, 13, 17, 19, 20, 30, 31]. A review of 6 cases from China reported immunocompromise, critical illness, and prior antifungals to be risks for invasive *A. lentulus* infections [15]. Reports suggest worse outcomes in patients with mixed *Aspergillus* infections [10, 19, 30]. Similar to other species, *A. lentulus* causes diverse radiographic findings, including consolidations [5, 12, 13, 19, 20], cavity lesions [5, 12, 31], and nodules [19].

It appears important to identify cryptic species of the *Aspergillus fumigatus* complex because they have different antifungal susceptibility patterns compared with *Aspergillus fumigatus sensu stricto*. A European study reviewed the largest collection of cryptic species, with 51 clinical isolates, 9 *A. lentulus*. Using EUKAST minimum inhibitory concentration (MIC) breakpoints, *A. lentulus* isolates showed high MICs to all triazoles and amphotericin B. It is one of the few cryptic species (with *A. udagawae*) that shows high MICs to both tri-azones and amphotericin [2]. Although many studies report high MICs to triazoles [4, 7, 15, 32–35], 1 reported favorable susceptibility to isavuconazole [36]. Intrinsic azole resistance appears to be cyp51A dependent [3, 37, 38]. Although there are no voriconazole clinical breakpoints for *Aspergillus lentulus*, applying breakpoints for *A. fumigatus* (susceptible ≤0.5 µg/mL; in-termediate 1 µg/mL; resistant ≥2 µg/mL) suggests voriconazole resistance in cases 1, 3, and 4, and intermediate resistance in case 2.

**LESSONS LEARNED**

Infections caused by cryptic species of the *Aspergillus fumigatus* complex are in the minority compared with *A. fumigatus sensu stricto*, but correct identification is important given poor out-comes associated with antifungal resistance. Laboratories may misidentify these species as *A. fumigatus* when only phenotypic methods are used. Providers should consider cryptic species if the laboratory describes an atypical *A. fumigatus* (poor sporulation) or if the lab reports *A. fumigatus* that is resistant to 1 or more triazoles or amphotericin B. In these situations, the prac-titioner should request additional investigation such as DNA sequencing to confirm the species identification. Alternatively, MALDI-TOF MS can be used as a rapid tool for presumptive identification of *A. lentulus*, but confirmation requires DNA sequencing. With increased *A. fumigatus* resistance and appreciate of cryptic species that have variable susceptibilities, increased reliance on susceptibility testing should be considered. Improvements in both species identification and antifungal sus-ceptibility testing could assist in the management of these com-plex invasive aspergillosis cases.

**Acknowledgments**

**Financial support.** None.

**Potential conflicts of interest.** S. Nematollahi: no financial disclo-sures. N. Permpalung: consulting/advisory board income from Shionogi Inc.; research grant from Cidara. S. X. Zhang: research grants from IMMY Diagnostics, Vela Diagnostics. M. Morales: no financial disclosures. K.A. Marr: consulting/advisory board income from Cidara, Merck, and Sfunga; equity and licensing revenue from MycoMed Technologies; research grant from Merck. All other authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Sugui JA, Peterson SW, Figat A, et al. Genetic relatedness versus biological com-patibility between *Aspergillus fumigatus* and related species. J Clin Microbiol 2014; 52:3707–21.

2. Imbert S, Normand AC, Cassaing S, et al. Multicentric analysis of the species dis-tribution and antifungal susceptibility of cryptic isolates from *Aspergillus section fumigati*. Antimicrob Agents Chemother 2020; 64:e01374–20.

3. Lamoth E. *Aspergillus fumigatus*-related species in clinical practice. Front Microbiol 2016; 7:683.
4. Balajee SA, Kano R, Raddley JW, et al. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47:3138–41.

5. Yagi K, Ushikubo M, Maeshima A, et al. Invasive pulmonary aspergillosis due to Aspergillus lentulus in an adult patient: a case report and literature review. J Infect Chemother 2019; 25:547–51.

6. Alastruey-Izquierdo A, Mellado E, Peláez T, et al; FILPOP Study Group. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother 2013; 57:3380–7.

7. Balajee SA, Weaver M, Imhof A, et al. Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother 2004; 48:1197–203.

8. Balajee SA, Grishkov JL, Hanley E, et al. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell 2005; 4:625–32.

9. Verwer PE, van Leeuwen WB, Girard V, et al. Discrimination of Aspergillus lentulus from Aspergillus fumigatus by Raman spectroscopy and MALDI-TOF MS. Eur J Clin Microbiol Infect Dis 2014; 33:245–51.

10. Alhambra A, Catalán M, Moragues MD, et al. Isolation of Aspergillus lentulus in Spain from a critically ill patient with chronic obstructive pulmonary disease. Rev Iberoam Microl 2008; 25:246–9.

11. Symoens F, Haese G, Pieth M, et al. Unusual Aspergillus species in patients with cystic fibrosis. Med Mycol 2010; 48:S10–6.

12. Bastos VR, Santos DW, Padovan AC, et al. Early invasive pulmonary aspergillosis in a kidney transplant recipient caused by Aspergillus lentulus: first Brazilian report. Mycopathologia 2015; 179:299–305.

13. Yoshida H, Seki M, Umezaya T, et al. Invasive pulmonary aspergillosis due to Aspergillus lentulus: successful treatment of a liver transplant patient. J Infect Chemother 2015; 21:479–81.

14. Parent-Michaud M, Dufresne PJ, Fournier E, et al. Prevalence and mechanisms of azole resistance in clinical isolates of Aspergillus section fumigati species in a Canadian tertiary care centre, 2000 to 2013. J Antimicrob Chemother 2020; 75:849–58.

15. Yu SY, Guo LN, Xiao M, et al. Clinical and microbiological characterization of invasive pulmonary aspergillosis caused by Aspergillus lentulus in China. Front Microbiol 2020; 11:1672.

16. Lysková P, Skružná M, Kubánek M, et al. Cryptic Aspergillus species - a case report of chronic cavitary pulmonary Aspergillus lentulus infection in a heart transplant recipient [in Czech]. Klin Mikrobiol Infekc Lek 2019; 25:48–52.

17. Gürçan S, Tıkveşi M, Ustaıdağ S, Ener B. A case report on Aspergillus lentulus pneumonia. Balkan Med J 2013; 30:429–31.

18. Frigiano A, Esposto MC, Grancini A, et al. Azole resistance in Aspergillus isolates by different types of patients and correlation with environment - an Italian prospective multicentre study (ARIA study). Mycoses 2021; 64:528–36.

19. Montenegro G, Sánchez Puch S, Lewtachowicz VM, et al. Phenotypic and genotypic characterization of Aspergillus lentulus and Aspergillus fumigatus isolates in a patient with probable invasive aspergillosis. J Med Microbiol 2009; 58:591–5.

20. Zbinden A, Imhof A, Wilhelm MJ, et al. Fatal outcome after heart transplantation caused by Aspergillus lentulus. Transpl Infect Dis 2012; 14:E60–3.

21. Kidé SE, Goeman E, Meis JF, et al. Multi-triazole-resistant Aspergillus fumigatus infections in Australia. Mycoses 2015; 58:350–5.

22. Mortensen KL, Johansen HK, Fruursted K, et al. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. Eur J Clin Microbiol Infect Dis 2011; 30:1355–63.

23. Pena GA, Alonso V, Manini MV, et al. Molecular characterization of Aspergillus fumigatus isolated from raw cow milk in Argentina: molecular typing of A. fumigatus from raw cow milk. Int J Food Microbiol 2018; 275:1–7.

24. Sabino P, Verissimo C, Parada H, et al. Molecular screening of 246 Portuguese Aspergillus isolates among different clinical and environmental sources. Med Mycol 2014; 52:519–29.

25. Barrs VR, Halliday C, Martin P, et al. Sinonasal and sino-oral aspergillosis in 23 cats: aetiology, clinicopathological features and treatment outcomes. Vet J 2012; 191:58–64.

26. Hong SB, Go SI, Shin HJ, et al. Polyphasic taxonomy of Aspergillus fumigatus and related species. Mycologia 2005; 97:1316–29.

27. Kaushik P, Malik A. Alkal, thermo and halo tolerant fungal isolate for the removal of textile dyes. Colloids Surf B Biointerfaces 2010; 81:321–8.

28. Singh NK, Wood JM, Karouia F, Venkateswaran K. Succession and persistence of microbial communities and antimicrobial resistance genes associated with international space station environmental surfaces. Microbiome 2018; 6:204.

29. Lago M, Aguier A, Natário A, et al. Does fungicide application in vineyards induce resistance to medical azoles in Aspergillus species? Environ Monit Assess 2014; 186:5581–93.

30. Escribano P, Peláez T, Muñoz P, et al. Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob Agents Chemother 2013; 57:2815–20.

31. Tetsuka N, Yaguchi T, Machida H, et al. Invasive pulmonary aspergillosis due to azole-resistant Aspergillus lentulus. Pediatr Int 2017; 59:362–3.

32. Tamiya H, Ochiai E, Kikuchi K, et al. Secondary metabolite profiles and antifungal drug susceptibility of Aspergillus fumigatus and closely related species, Aspergillus lentulus, Aspergillus udagawae, and Aspergillus viridinutans. J Infect Chemother 2015; 21:385–91.

33. Won EJ, Shin JH, Kim SH, et al. Antifungal susceptibilities to amphotericin B, triazoles and echinocandins of 77 clinical isolates of cryptic Aspergillus species in multicenter surveillance in Korea. Med Mycol 2018; 56:501–5.

34. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, et al. Aspergillus section fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother 2008; 52:1244–51.

35. Pinto E, Monteiro C, Maia M, et al. Aspergillus species and antifungals susceptibility in clinical setting in the north of Portugal: cryptic species and emerging azoles resistance in A. fumigatus. Front Microbiol 2018; 9:1656.

36. Datta K, Rhee P, Byrnes E 3rd, et al. Isavaconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility. J Clin Microbiol 2013; 51:3090–3.

37. Mellado E, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Role of Aspergillus lentulus 14-α sterol demethylase (Cyp51A) in azole drug susceptibility. Antimicrob Agents Chemother 2011; 55:5459–68.

38. Alastruey-Izquierdo A, Alcazar-Fuoli L, Cuenca-Estrella M. Antifungal susceptibility profile of cryptic species of Aspergillus. Mycopathologia 2014; 178:427–33.